Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 17/20 | 1.00 |
| ▸ | ADORA1 | P30542 | 15/20 | 1.00 |
| ▸ | ADORA2B | P29275 | 13/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 11/20 | 1.00 |
| ▸ | PI4KA | P42356 | 3/20 | 0.54 |
| ▸ | PI4K2B | Q8TCG2 | 3/20 | 0.54 |
| ▸ | PI4K2A | Q9BTU6 | 3/20 | 0.54 |
| ▸ | PI4KB | Q9UBF8 | 3/20 | 0.54 |
| ▸ | FBP1 | P09467 | 1/20 | 0.50 |
| ▸ | NADK | O95544 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31061173 | 0.98 | ADORA2A (1.00) | ADORA2AADORA1ADORA2BADORA3PI4KA | |
| SCHEMBL31061415 | 0.97 | ADORA2A (1.00) | ADORA2AADORA1ADORA2BADORA3PI4KA | |
| SCHEMBL3520232 | 0.83 | ADORA2A (0.70) | ADORA2AADORA1ADORA2BADORA3PI4KA | |
| SCHEMBL5732265 | 0.82 | ADORA2A (0.69) | ADORA2AADORA1ADORA2BADORA3PI4KA | |
| SCHEMBL3520300 | 0.82 | ADORA2A (0.68) | ADORA2AADORA1ADORA2BADORA3FBP1 | |
| SCHEMBL3517750 | 0.75 | ADORA2A (0.59) | ADORA2AADORA1ADORA2BADORA3 | |
| SCHEMBL10379475 | 0.73 | ADORA2A (0.68) | ADORA2AADORA1ADORA2BADORA3NADK | |
| SCHEMBL29709122 | 0.72 | ADORA2A (0.56) | ADORA2AADORA1ADORA2BADORA3NADK | |
| SCHEMBL29328691 | 0.72 | ADORA2A (0.56) | ADORA2AADORA1ADORA2BADORA3NADK | |
| SCHEMBL4954196 | 0.72 | ADORA2A (0.61) | ADORA2AADORA1ADORA2BADORA3FBP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4662319-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | Integrate Bioscience LLC (US) | 2025-12-17 | — | — | EP | disclosed |
| WO-2024168301-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | FUNCTION ONCOLOGY, INC. (US) | 2024-08-15 | — | — | WO | disclosed |
| EP-1043021-B1 | PURINE DERIVATIVES FOR THE TREATMENT OF ALLERGIC DISEASES AND SYSTEMIC LUPUS ERYTHEMATOSUS | DAINIPPON SUMITOMO PHARMA CO (JP) | 2006-05-03 | — | — | EP | disclosed |
| EP-0882727-B9 | NOVEL PURINE DERIVATIVES | SUMITOMO PHARMA (JP) | 2005-06-15 | — | — | EP | disclosed |
| EP-0882727-B1 | NOVEL PURINE DERIVATIVES | SUMITOMO PHARMA (JP) | 2004-12-01 | — | — | EP | disclosed |
| US-6376501-B1 | INHIBITING OR REGULATING IMMUNE RESPONSE USING PURINE-DERIVED COMPOUND; NON-STEROIDAL COMPOUND | JAPAN ENERGY CORPORATION (JP) | 2002-04-23 | — | — | US | disclosed |
| EP-1043021-A1 | TYPE 2 HELPER T CELL-SELECTIVE IMMUNE RESPONSE SUPPRESSORS | Japan Energy Corporation (JP) | 2000-10-11 | — | — | EP | disclosed |
| US-6028076-A | FOR INDUCING .ALPHA.-INTERFERON IN A PATIENT HAVING HEPATITIS B OR C, BY ADMINISTERING PURINE DERIVATIVE | JAPAN ENERGY CORPORATION (JP) | 2000-02-22 | — | — | US | disclosed |
| EP-0882727-A1 | NOVEL PURINE DERIVATIVES | JAPAN ENERGY CORPORATION (JP) | 1998-12-09 | — | — | EP | disclosed |